MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
27.72
-0.10
-0.36%
After Hours: 27.99 +0.27 +0.97% 19:54 12/31 EST
OPEN
27.95
PREV CLOSE
27.82
HIGH
28.00
LOW
27.46
VOLUME
869.14K
TURNOVER
--
52 WEEK HIGH
35.25
52 WEEK LOW
13.53
MARKET CAP
2.81B
P/E (TTM)
-6.2504
1D
5D
1M
3M
1Y
5Y
1D
ARK outperforms in 2025 With Tesla still Cathie Wood’s biggest bet
Seeking Alpha · 16h ago
Cathie Wood Wraps Up 2025 with New Biotech Buys — Here’s What It Sold
TipRanks · 20h ago
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
Benzinga · 12/31/2025 22:06
Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets
TipRanks · 12/31/2025 04:22
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
Seeking Alpha · 12/29/2025 13:15
Weekly Report: what happened at BEAM last week (1222-1226)?
Weekly Report · 12/29/2025 10:18
Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy
Simply Wall St · 12/24/2025 23:56
Beam Therapeutics (BEAM) Receives a Buy from Evercore ISI
TipRanks · 12/24/2025 11:45
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.